LOGIN  |  REGISTER
Surmodics

Ekso Bionics (NASDAQ: EKSO) Stock Quote

Last Trade: US$1.36 -0.06 -4.23
Volume: 357,021
5-Day Change: -2.16%
YTD Change: -45.60%
Market Cap: US$24.340M

Latest News From Ekso Bionics

Sold Record Number of Annual EksoHealth Units in 2023 SAN RAFAEL, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2023. Recent Highlights and Accomplishments Achieved record revenue of $18.3 million for the 2023... Read More
SAN RAFAEL, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2023 after the close of trading on Monday, March 4, 2024. Management will host a conference call beginning at 1:30 p.m. PT / 4:30... Read More
SAN RAFAEL, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 2,967,742 shares of common stock at a purchase price of $1.55 per share pursuant to a registered... Read More
SAN RAFAEL, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced the launch of GaitCoach™, its next generation gait therapy software for EksoNR. GaitCoach is a comprehensive gait therapy software that supports a broad spectrum of patients who use EksoNR. This new software simplifies... Read More
SAN RAFAEL, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial results for the fourth quarter and fiscal year ended December 31, 2023. Total revenue for the fourth quarter of 2023 is estimated to be in the range of $4.7 million to $4.9 million, compared... Read More
SAN RAFAEL, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that the Pricing, Data Analysis, and Coding (“PDAC”) contractor for the Centers for Medicare & Medicaid Services (“CMS”) has completed its review of the Ekso Indego Personal and approved use of Healthcare Common Procedure... Read More
SAN RAFAEL, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that the Company will participate at the Centers for Medicare & Medicaid Services’ (“CMS”) Healthcare Common Procedure Coding System (“HCPCS”) public meeting on November 29, 2023, to discuss appropriate Medicare payment... Read More
Ruling Could Significantly Expand Use of Ekso Indego Personal in Home and Community Markets SAN RAFAEL, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, announces that the Centers for Medicare & Medicaid Services (“CMS”) finalized its Calendar Year 2024 Home Health Prospective Payment System Rule... Read More
SAN RAFAEL, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and nine months ended September 30, 2023. Recent Highlights and Accomplishments Reported revenue of $4.6 million in the third quarter of 2023, an increase of 38% year-over-year Sold a total... Read More
SAN RAFAEL, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2023 after the close of trading on Thursday, October 26, 2023. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to... Read More
SAN RAFAEL, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, supports the Centers for Medicare & Medicaid Services (“CMS”) proposal to include personal exoskeletons in the Medicare benefit category for braces in the updated 2024 Home Health Prospective Payment System Rate. “This newly proposed... Read More
SAN RAFAEL, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Scott Davis, Chief Executive Officer, and Jerome Wong, Chief Financial Officer, will be participating in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference taking place in New York on... Read More
SAN RAFAEL, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2023. Recent Highlights and Accomplishments Achieved record revenues of $4.7 million in the second quarter of 2023, an increase of 36% year-over-year Booked a... Read More
SAN RAFAEL, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2023 after the close of trading on Thursday, July 27, 2023. Management will host a conference call beginning at 1:30 p.m. PT /... Read More
Highest Quarterly Revenues in Company History SAN RAFAEL, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2023. Recent Highlights and Accomplishments Achieved record revenues of $4.1 million in the first... Read More
SAN RAFAEL, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2023 after the close of trading on Thursday, April 27, 2023. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to... Read More
SoldierStrong to Donate Device to the Charlie Norwood Department of Veteran Affairs Medical Center in Augusta, GA SAN RAFAEL, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that SoldierStrong, a non-profit organization dedicated to improving Veterans’ lives through innovative technology, has... Read More
SAN RAFAEL, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2022. Recent Highlights and Accomplishments Completed the acquisition of the Human Motion Control (“HMC”) business unit including the Indego ® product... Read More
SAN RAFAEL, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2022 after the close of trading on Tuesday, March 28, 2023. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to... Read More
SAN RAFAEL, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced it will showcase the new Ekso Indego Therapy with Functional Electrical Stimulation (FES) at the upcoming American Physical Therapy Association’s Combined Sections Meeting on February 23-25 in San Diego, California. The Company recently... Read More
Surmodics

COPYRIGHT ©2023 HEALTH STOCKS HUB